170 related articles for article (PubMed ID: 20596644)
1. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma.
Sasaki A; Kamiyama T; Yokoo H; Nakanishi K; Kubota K; Haga H; Matsushita M; Ozaki M; Matsuno Y; Todo S
Oncol Rep; 2010 Aug; 24(2):537-46. PubMed ID: 20596644
[TBL] [Abstract][Full Text] [Related]
2. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K
Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363
[TBL] [Abstract][Full Text] [Related]
3. Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis.
Kim H; Choi GH; Na DC; Ahn EY; Kim GI; Lee JE; Cho JY; Yoo JE; Choi JS; Park YN
Hepatology; 2011 Nov; 54(5):1707-17. PubMed ID: 22045674
[TBL] [Abstract][Full Text] [Related]
4. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma.
Chan AW; Tong JH; Chan SL; Lai PB; To KF
Histopathology; 2014 Jun; 64(7):935-50. PubMed ID: 24506513
[TBL] [Abstract][Full Text] [Related]
5. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis.
Ma YC; Yang JY; Yan LN
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1007-16. PubMed ID: 23478672
[TBL] [Abstract][Full Text] [Related]
6. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection.
Yeh CT; Kuo CJ; Lai MW; Chen TC; Lin CY; Yeh TS; Lee WC
BMC Cancer; 2009 Sep; 9():324. PubMed ID: 19744348
[TBL] [Abstract][Full Text] [Related]
7. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection.
Sun YF; Xu Y; Yang XR; Guo W; Zhang X; Qiu SJ; Shi RY; Hu B; Zhou J; Fan J
Hepatology; 2013 Apr; 57(4):1458-68. PubMed ID: 23175471
[TBL] [Abstract][Full Text] [Related]
8. The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients.
Chen YL; Lin PY; Ming YZ; Huang WC; Chen RF; Chen PM; Chu PY
BMC Cancer; 2017 Jul; 17(1):474. PubMed ID: 28687090
[TBL] [Abstract][Full Text] [Related]
9. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma.
Guo Z; Li LQ; Jiang JH; Ou C; Zeng LX; Xiang BD
World J Gastroenterol; 2014 Feb; 20(8):2098-106. PubMed ID: 24616575
[TBL] [Abstract][Full Text] [Related]
10. Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer.
Hashimoto K; Aoyagi K; Isobe T; Kouhuji K; Shirouzu K
Gastric Cancer; 2014 Jan; 17(1):97-106. PubMed ID: 23558457
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological characteristics of 20 cases of hepatocellular carcinoma with bile duct tumor thrombi.
Yu XH; Xu LB; Liu C; Zhang R; Wang J
Dig Dis Sci; 2011 Jan; 56(1):252-9. PubMed ID: 20437099
[TBL] [Abstract][Full Text] [Related]
12. Biology and clinical implications of CD133(+) liver cancer stem cells.
Ma S
Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
[TBL] [Abstract][Full Text] [Related]
13. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients.
Takahashi S; Kamiyama T; Tomaru U; Ishizu A; Shida T; Osaka M; Sato Y; Saji Y; Ozaki M; Todo S
Oncol Rep; 2010 Nov; 24(5):1201-12. PubMed ID: 20878111
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma.
Kohga K; Tatsumi T; Takehara T; Tsunematsu H; Shimizu S; Yamamoto M; Sasakawa A; Miyagi T; Hayashi N
J Hepatol; 2010 Jun; 52(6):872-9. PubMed ID: 20395004
[TBL] [Abstract][Full Text] [Related]
15. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
[TBL] [Abstract][Full Text] [Related]
16. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity.
Yin S; Li J; Hu C; Chen X; Yao M; Yan M; Jiang G; Ge C; Xie H; Wan D; Yang S; Zheng S; Gu J
Int J Cancer; 2007 Apr; 120(7):1444-50. PubMed ID: 17205516
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma.
Lingala S; Cui YY; Chen X; Ruebner BH; Qian XF; Zern MA; Wu J
Exp Mol Pathol; 2010 Aug; 89(1):27-35. PubMed ID: 20511115
[TBL] [Abstract][Full Text] [Related]
18. Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma.
Zhang C; Xu Y; Zhao J; Fan L; Jiang G; Li R; Ling Y; Wu M; Wei L
Ann Surg Oncol; 2011 Aug; 18(8):2373-80. PubMed ID: 21331808
[TBL] [Abstract][Full Text] [Related]
19. Invasion and EMT-associated genes are up-regulated in B viral hepatocellular carcinoma with high expression of CD133-human and cell culture study.
Na DC; Lee JE; Yoo JE; Oh BK; Choi GH; Park YN
Exp Mol Pathol; 2011 Feb; 90(1):66-73. PubMed ID: 20969862
[TBL] [Abstract][Full Text] [Related]
20. The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma.
Hagiwara S; Kudo M; Ueshima K; Chung H; Yamaguchi M; Takita M; Haji S; Kimura M; Arao T; Nishio K; Park AM; Munakata H
J Gastroenterol; 2011 Feb; 46(2):212-21. PubMed ID: 20683621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
